BofA raises Thermo Fisher (TMO) target as biopharma recovery comes into view
I'm PortAI, I can summarize articles.
Bank of America has raised its price target for Thermo Fisher Scientific Inc. (NYSE:TMO) from $650 to $700, maintaining a Buy rating. The company is also listed among the 14 Best Pharma Dividend Stocks to Buy in 2026, indicating a positive outlook as the biopharma sector recovers.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments